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Objective: 11β-dehydroxysteroid dehydrogenase (HSD) types 1 and 2,
enzymes are involved in the activation and inactivation of glucocorticoids
in vivo, respectively. Indirect evidence implicates two enzymes in the
aetiology of depression but no study has directly assessed the potential
role of 11 β-HSD1 in animal tests.
Methods: We assessed 11 β-HSD1 knockout mice in the forced swim
test (FST), tail suspension test (TST) and for locomotor activity.
Results: Genetic ablation of the 11β-HSD1 gene results in an
antidepressant-like phenotype in the FST; the most widely utilised animal
test of antidepressant activity, but not in the related TST. This may be
related to the different biological substrates underlying these tests. The
decreased FST immobility was not due to alterations in general activity.
Conclusions: Taken together these results suggest that 11β-HSD1 may
play an important role in depression-related behaviours and further
studies are necessary to fully characterise its role in such behaviour.
Signﬁcant outcomes
∙ 11β-dehydroxysteroid dehydrogenase type 1 (11β-HSD1) knockout results in an antidepressive-like
phenotype in mice.
∙ Provides further evidence for the neurobiological dissociation between the forced swim test (FST) and
tail suspension test (TST) as tests for antidepressant-like activity.
Limitations
∙ Heterozygous mice were not included in the study.
∙ Further behavioural tests, such as for anxiety, or social behaviour, were not assessed in the present study.
Moreover, the behavioural phenotype following chronic stress exposure was not addressed.
Introduction
The aetiology of depression remains poorly under-
stood despite substantial research efforts over the last
50 years. It is clear that exposure to chronic or
traumatic stress plays a role in the pathogenesis of
major depressive disorder and this has allowed a
glucocorticoid theory of depression (1,2) to develop.
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Indeed one of the most consistent ﬁndings in patients
with major depression – is altered activity of the
hypothalamic–pituitary–adrenal (HPA) axis [reviewed
by (1,2)]; although negative ﬁndings have also been
reported (3). Thus, increased levels of cortisol in the
plasma, CSF and urine, as well as a hyper-cortisol
response to adrenocorticotropic hormone (ACTH)
have been demonstrated in patients with major
depression. In contrast, it has also been shown that
chronically depressed patients, and those with ‘burn
out’, can display decreased cortisol levels (4),
suggesting that deviation from appropriate HPA axis
activity may be associated with major depression.
Furthermore, enlarged pituitary and adrenal glands
have also been reported in major depression and it is
believed that these physiological adaptations are the
result of increased hypothalamic secretion of
corticotrophin-releasing factor (CRF) (1,2). In fact,
the combined dexamethasone (DEX)/CRF test,
which takes plasma cortisol as its readout, has been
put forward as a diagnostic marker in depression (5).
DEX binds to peripheral glucocorticoid receptors
(GR), which results in decreased ACTH synthesis
and secretion, and, consequently, cortisol secretion in
control subjects (5). This DEX-mediated suppression
of cortisol is impaired in, at least a subset of,
depressed patients. However, in other patients the
response quickly normalizes despite the maintenance
of clinical depression suggesting it may be a better
surrogate of stress [reviewed in (5)]. This, together
with numerous studies assessing GR number, afﬁnity
and efﬁcacy, support the view that GR function is
altered in patients with major depression (2).
The altered cortisol levels reported in depressed
patients play a signiﬁcant role in the altered functioning
of GRs, as it is the main substrate (2). Furthermore,
Cushing’s syndrome, characterised by excessive
circulating levels of cortisol, and adrenal hyperplasia
are often associated with major depression (6).
Two enzymes, both 11β-HSDs, provide the
principle pathways for the interconversion of active
and inactive glucocorticoids, corticosterone and 11β-
dehydrocorticosterone (DHC) in rodents, respectively
(cortisol and cortisone in humans). 11β-HSD type 1
(11β-HSD1) is a reductase enzyme that acts together
with its cofactor NADP(H) to reactivate 11β-DHC
in vivo (although in vitro it acts bidirectionally), which
leads to increased local glucocorticoid activity.
Conversely, 11β-HSD type 2 (11β-HSD2) inactivates
corticosterone, with its cofactor NAD and is located
primarily in regions containing mineralocorticoid
receptors (MR) in order to prevent excessive
glucocorticoid activation of MRs. It has also been
demonstrated in vitro that there is a positive feedback
system in place whereby applicaton of cortisol
increases 11β-HSD1 mRNA expression (7). The two
enzymes also have a differential distribution
throughout the body, with high levels of 11β-HSD1
being observed in the liver, adipose tissue and the
brain, whereas 11β-HSD2 is primarily located in the
kidney, placenta and the brain (8). More speciﬁcally
within the brain, 11β-HSD1 shows a widespread
distribution, in the hippocampus, hypothalamus,
brainstem, cerebellum and cortex whereas 11β-
HSD2 expression is conﬁned to discrete nuclei
controlling blood pressure and salt balance, such as
the lateral hypothalamus and nucleus tractus
solitarius (8).
Therefore, given their roles, it has been hypothesised
that targeting of these two enzymes may be of
therapeutic beneﬁt to a wide range of disorders, from
metabolic diseases to major depressive disorder.
However, to date the evidence for their involvement
in major depressive disorder is mostly circumstantial,
such as ﬁndings from clinical studies suggesting that
depressed patients have reduced activity of 11β-HSD
compared with controls; although it was not possible to
differentiate between type 1 and type 2 (9). More
recently, it has been observed that a single-nucleotide
polymorphism in the 11 β-HSD1 gene was associated
with elevated salivary cortisol and a higher risk for the
incidence of depression (10).
Genetic ablation of 11β-HSD1 and/or 11β-HSD2
results in viable mice and have been extensively
characterised in relation to metabolic and
inﬂammatory processes [see (8) for review]. Thus,
11β-HSD1− /− mice have been shown to have enlarged
adrenals, to maintain a diurnal corticosterone rhythm
but with an earlier peak and demonstrate an elevated
and prolonged stress response (11). Furthermore,
pre-treatment with corticosterone (5 mg/kg, i.p.)
10 min before restraint stress lead to a further initial
rise in corticosterone compared with wild-type mice
(11). While 11β-HSD2− /− ablation is associated with
an anxiogenic and depressive phenotype (for review
see (12)), it is not known whether 11β-HSD1− /− mice
have an altered phenotype in behavioural tests relevant
to depression and the antidepressant response.
Aims of the study
Therefore, the aim of the present study was to assess
the impact of constitutive knockout of the 11β-HSD1
gene on depressive-like behaviour in mice. In order
to do so, the FST and TST, two of the most
commonly utilised preclinical tests of antidepressant
activity, were performed. These tests are locomotor
based and can often result in false negative or
positive results. Therefore, in order to control for
possible alterations in general locomotor activity,
mice were assessed for locomotor activity in a novel
environment.
Slattery et al.
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Materials and methods
Animals
Male 11β-HSD1+ /+ and 11β-HSD1− /− mice weighing
30–46 g at the start of the experimental period were
used in the present studies. The animals were housed
in groups of 2–4 and maintained on a 12-h light : dark
cycle (lights on 06:00 a.m.) in a temperature-
controlled colony (22–24°C). The animals had free
access to food and water. Animals were allowed to
habituate for at least 7 days before surgery. All
experimental procedures were subject to institutional
review and conducted in accordance with the
Veterinary Authority of Basel-Stadt, Switzerland.
Behavioural studies
FST. The FST was performed as previously
described (13–15). Brieﬂy, mice were placed
individually into plexiglass cylinders (24 × 21 cm),
which were ﬁlled to a depth of 15 cm with water
(25± 1°C). The mice were removed after 6 min,
dried and returned to a new cage. Water was changed
between each test. A video camera placed directly
above the cylinder recorded each test session for
subsequent analysis. The rater of the test session was
blind to the genetic background being scored. The
behavioural measure scored was immobility time
during the ﬁnal 4 min of the 6-min test period as
previously validated (13,16).
TST. One week after the completion of the FST
test the mice were subjected to the TST test, which
was performed as previously described (13,14).
Brieﬂy, mice were individually suspended by the
tail to a hook using adhesive tape (distance to the
tip of the tail = 2 cm). A video camera placed
directly in front of the mice recorded each test
session for subsequent analysis. The rater of the
test session was blind to the genetic background
being scored. The behavioural measure scored was
immobility during the entire 6 min test session as
previously validated (13). Four mice were excluded
from behavioural analysis (one wildtype and three
KO); two fell off, one grabbed the edge of the TST
box and one climbed its tail.
Locomotor activity. A possible confound of the
above two behavioural tests is differences in base-
line locomotor activity (17), which can result in
false positive results. Therefore, the mice were
assessed for locomotor activity over a 30 min
period. One week following the TST test, animals
were placed in automated locomotor activity cages
(31 cm length, 19 cm width, 16 cm height; TSE,
Bad Homberg, Germany). Distance travelled was
measured by the number of beam-breaks as pre-
viously described (14). Data were collected using a
personal computer in 5 min intervals. All mice were
experimentally naïve to the locomotor test cage.
Statistics
FST and TST were analysed using Student’s t-test
and locomotor activity was analysed using a repeated
measures ANOVA and Student’s t-test using SPSS
v12. The level of signiﬁcance was set at p< 0.05.
Results
FST
The FST is one of the most utilised, and validated,
animal tests of antidepressant-like phenotypes in
genetically-modiﬁed mice. Here we demonstrate that
11β-HSD1− /− mice display a signiﬁcant reduction
in immobility time compared with wildtype mice
[Fig. 1a; t(22) = 13.447; p< 0.001].
TST
Another well-validated animal test predictive of a
depressive- or antidepressant-like phenotype follow-
ing pharmacological or genetic manipulation is
the TST. Unlike the results of the FST, genetic
deletion of 11 β-HSD1 did not result in a signiﬁcant
difference in behaviour in this test [Fig. 1b;
t(18) = 1.562; ns].
Locomotor activity
In order to rule out the possibility that the results
obtained from the FST and TST were inﬂuenced by
differences in locomotor activity, mice were tested in
a novel environment for horizontal activity. No
signiﬁcant difference in locomotor activity between
the genotypes was observed for any of the 5 min bins
of the 30 min test (F1,22 = 0.28; p> 0.05) or of total
distance travelled [Fig. 2 inset; t(22) = 0.27, ns].
Discussion
The present study demonstrates that constitutive
knockout of the 11β-HSD1 gene results in an
antidepressant-like phenotype as revealed by a
signiﬁcant reduction in immobility time in the FST.
This decrease in immobility was speciﬁc as a
separate test on general locomotor activity did not
reveal signiﬁcant differences between 11β-HSD1− /−
and wildtype mice. These results conﬁrm the
involvement of 11β-HSD1 in depression and
antidepressant-related behaviour.
11β-HSD type 1 and depression
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The glucocorticoid theory of major depression
postulates that an excess of circulating
glucocorticoids, leading to hyperactivity of the
HPA axis, which in turn causes damage to relevant
brain structures, such as the hippocampus. A key
enzyme involved in the conversion of inactive
to active glucocorticoids is 11β-HSD1. Despite
numerous studies indirectly suggesting that this
enzyme may be involved in depression and
depression-related behaviour, this is the ﬁrst study
to directly examine 11β-HSD1 in animal tests of
depressive-like/antidepressant-like behaviour. Genetic
deletion of 11β-HSD1 was shown to signiﬁcantly
reduce immobility time in the FST compared with
wildtype mice (Fig. 1a); one of the most widely
used preclinical tests of antidepressant activity (17).
This striking reduction in immobility time suggests
that deletion of the main enzyme responsible for
the activation of 11-DHC to corticosterone leads
to an antidepressant-like phenotype. However, no
difference was observed in the TST (Fig. 1b), which
is another commonly utilised mouse test of
antidepressant efﬁcacy. This ﬁnding, while initially
seeming incongruous may be a result of the different
biological substrates that underlie the behaviour
in both tests (18). Thus, while the mouse FST
can be insensitive to SSRIs they are generally
reported as active in the TST [for reviews, see
(18,19)]. Furthermore, both genetic ablation and
pharmacological antagonism of GABAB receptors
have been shown to reduce immobility in the FST but
not in the TST [see (18) for review]. There are also
examples whereby treatments are active only in
the TST, most notably the atypical antidepressants
rolipram and levoprotiline (19). Therefore, the lack
of response in the TST does not negate the
antidepressant-like phenotype witnessed in the
FST. However, until the underlying biological
substrates of these two tests are determined it
remains unclear as to which systems may be more
important for the antidepressant phenotype observed
in 11β-HSD1− /− mice.
The altered behaviour in the FST cannot be due to
deﬁcits in locomotor activity caused by ablation of
the 11β-HSD1 gene as no difference was observed in
general locomotion in a novel environment (Fig. 2).
This suggests that increased conversion of 11-DHC
to corticosterone is not required for the initially high
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Fig. 1. Antidepressant-like behaviour of 11β-HSD1− /− mice. (a) 11β-HSD1− /− mice (n = 12) display reduced immobility time in the
forced swim test (FST) compared with WT (n = 12) indicative of an antidepressant-like effect. (b) No difference in immobility time
between 11β-HSD1− /− mice (n = 9) and WT (n = 11) was observed in the tail suspension test (TST). Data represent mean±SEM.
Student’s t-test was performed for each test with ***p< 0.001. 11β-HSD = 11β-dehydroxysteroid dehydrogenase type 1.
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Fig. 2. Deletion of the 11β-dehydroxysteroid dehydrogenase type 1 (11β-HSD1) gene does not alter spontaneous locomotor activity.
(a) 11β-HSD1− /− mice (n = 12) display reduced immobility time in the forced swim test (FST) compared with 11β-HSD1+ / + mice
(n = 12) indicative of an antidepressant-like effect. Data represent mean±SEM. Student’s t-test and repeated measures ANOVA was
performed.
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level of locomotor activity observed when a rodent is
placed into a novel environment. More importantly
for the present study, this implies that the decreased
immobility time in the FST is related to an
antidepressant-like phenotype and not to altered
activity. Furthermore, 11β-HSD1− /− mice do not
display an altered anxiety-phenotype compared with
wildtype mice in the elevated plus maze or open ﬁeld
tests [see (12) for review]. Therefore, the observed
antidepressant-like phenotype in 11β-HSD1− /− mice
in the FST would seem to be a speciﬁc phenomenon.
The altered diurnal corticosterone rhythm in
11β-HSD1− /− mice, with an earlier rise, which
coincides with the time when the present studies
were performed (11), and the elevated corticosterone
response exhibited in response to restraint stress
would make it seem paradoxical that such mice
exhibit antidepressant-like activity. However, a
number of additional factors must also be
considered, which suggest that despite elevated
corticosterone levels 11β-HSD1− /− mice have
attenuated glucocorticoid action within cells. Thus,
despite the increased adrenal weight, 11β-HSD1− /−
mice were revealed to produce less corticosterone
in vitro in response to an ACTH challenge (20).
Furthermore, corticosteroid-binding globulin (CBG)
levels do not differ between 11β-HSD1+ / + and 11β-
HSD1− /− mice, suggesting that despite the elevated
circulatory corticosterone the majority is bound to
CBG preventing it from binding to GR. In addition,
11β-HSD1− /− mice, while having the same GR, MR
and CRH mRNA levels in the hippocampus have
been shown to have decreased GR mRNA expression
within the PVN (11). Therefore, this, together with
the lack of 11β-HSD1 in the negative feedback sites
would lead to both decreased regeneration of
corticosterone and decreased GR receptors for
corticosterone to act, attenuating the negative
feedback response.
It has been proposed, at least in the elderly
population that both hypo- and hyper-cortisolemia is
associated with major depression (4). Therefore,
dysregulation of 11β-HSD1 would appear to play
an important role, at least in the elderly population,
both in relation to cognitive decline and major
depression. Further support comes from human
studies showing that depressed patients have lower
11β-HSD activity compared with controls (9). The
activity is approximated from the levels of various
steroid metabolites and as such cannot distinguish
between the activities of the two forms of the enzyme
(12). Therefore, the current studies imply that
11β-HSD1 activity may underlie these ﬁndings
as the ablation of 11β-HSD1 resulted in an
antidepressant-like phenotype; despite unaltered
activity of 11β-HSD2, as previously reported.
In summary, the present study demonstrates that
ablation of the 11β-HSD1 gene results in an
antidepressant-like phenotype in mice in the FST,
which together with previous ﬁndings in 11 β-HSD2
knockout mice suggests a bidirectional effect these
enzymes on depressive-like behaviour.
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